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ABSTRACT: We tested the effects of relaxin on [Ca2+]i response to angiotensin
II in smooth muscle (vSMC) and endothelial cells isolated from hypertensive
(SHR) and normotensive (WKY) rats. Relaxin markedly reduced the [Ca2+]i
response of vSMCs from WKY, but not from SHR rats. Western blots showed
that cGMP-dependent protein kinase G was reduced in vSMCs from SHR as
compared with WKY rats. Relaxin also blunted the [Ca2+]i response in endo-
thelial cells from WKY, but not from SHR rats. However, in endothelial cells
from SHR and WKY rats, protein kinase G was nearly unexpressed, thus
accounting for an alternative pathway of the intracellular response to nitric
oxide and relaxin. Hence, vSMCs and endothelial cells in SHR rats show a
deficiency response to nitric oxide that may render them insensitive to relaxin.
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INTRODUCTION
Relaxin has striking vasodilatory properties on reproductive and nonreproductive
organs.1,2 When given systemically to spontaneously hypertensive rats (SHR strain),
relaxin reduces systemic blood pressure and blunts the vascular response to vasocon-
strictors.3,4 These properties of relaxin likely rely on multiple mechanisms. In vitro
studies have shown that relaxin increases the expression of inducible nitric oxide
synthase (NOS II) in rat endothelial cells (ECs) and vascular smooth muscle cells
(vSMCs). By this pathway, relaxin reduced vasoconstrictor-induced increases in
intracellular calcium concentration [Ca2+]i and promoted cell relaxation.5,6
This in vitro study was designed to compare the effects of relaxin (porcine) on the
[Ca2+]i response to angiotensin II (AT II) by vSMCs and ECs isolated from sponta-
neously hypertensive (SHR) rats or normotensive Wistar-Kyoto (WKY) rats.
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MATERIAL AND METHODS
We used eight SHR and nine WKY rats 12–14 wk old. Endothelial cells were iso-
lated from rat hearts by enzymatic digestion and selected from other cardiac cell
types by centrifugation and adhesion to plastic surfaces. Aortic vSMCs were isolated
by elastase-collagenase digestion of endothelium-free thoracic aortas and used
between the second and fourth culture passage. Cells plated on glass coverslips were
loaded with fura-2 AM and used for intracellular calcium [Ca2+]i image analysis
assay in control conditions or after a 24-h pretreatment with porcine relaxin (10−8
M). Angiotensin II (AT II, 10−6 M) was used as the vasoactive stimulus. Untreated
and relaxin-treated cell cultures seeded in 25 cm2 culture flasks were also used for
western blot analysis of protein kinase G expression.
Vascular Smooth Muscle Cells
Resting [Ca2+]i  and AT II-induced [Ca2+]i peak and decay times were similar in
SHR and WKY rats. In vSMCs from WKY rats, relaxin (10 nM) decreased the decay
time and peak values of [Ca2+]i transiently. This effect was prevented when the cells
were pretreated with the NOS inhibitor L-NAME (10 mM), suggesting the involve-
ment of endogenous nitric oxide generation. Conversely, vSMCs from SHR rats
were insensitive to relaxin as well as to L-NAME. By western blotting, vSMCs from
WKY rats fairly expressed protein kinase G, whereas those from SHR rats only
showed very weak protein kinase G expression.
Endothelial Cells
Resting [Ca2+]i was higher in SHR than in WKY rats (144 ± 7.4 vs 109 ± 4.0 nM;
P <0.01). The AT II-induced increase in [Ca2+]i was characterized by a fast rise fol-
lowed by a slower decrease in both WKY and SHR rats. [Ca2+]i peak and decay
times (time needed to return to basal values) were similar in SHR and WKY rats.
In ECs from WKY rats, relaxin (10 nM) significantly decreased the decay time
and peak values of [Ca2+]i transiently. This effect was prevented when the cells were
pretreated with L-NAME (10 mM), suggesting involvement of endogenous nitric ox-
ide generation. Conversely, ECs from SHR rats were insensitive to relaxin as well as
to L-NAME. By western blotting, ECs from either WKY or SHR rats did not express
detectable protein kinase G.
RESULTS AND CONCLUSIONS
This study shows that ECs and vSMCs from SHR rats have a deficiency response
to nitric oxide that renders them insensitive to the relaxant action of relaxin. This
appears to depend on a defect in the expression of cGMP-dependent protein kinase
G by vSMCs, the cells chiefly involved in the regulation of vascular tone, which
leads to a breakdown of the nitric oxide-cGMP signaling pathway. These findings
support the pivotal role of nitric oxide-cGMP signaling in the vasorelaxant effects of
relaxin. Conceivably, the reduction of arterial blood pressure in SHR rats given
relaxin systemically reported in previous studies may rely on alternative, nitric
oxide-independent mechanisms.
313FAILLI et al.: RELAXIN AND VASCULAR CELLS IN WKY AND SHR RATS
REFERENCES
1. BANI, D. 1997. Relaxin: a pleiotropic hormone. Gen. Pharmacol. 28: 13–22.
2. SHERWOOD, O.D. 2004. Relaxin's physiological roles and other diverse actions. Endocr.
Rev. 25: 205–234.
3. ST. LOUIS, J. & G. MASSICOTTE. 1985. Chronic decrease of blood pressure by rat
relaxin in spontaneously hypertensive rats. Life Sci. 37: 1351–1357.
4. MASSICOTTE, G., A. PARENT & J. ST. LOUIS. 1989. Blunted responses to vasoconstric-
tors in mesenteric vasculature but not in portal vein of spontaneously hypertensive
rats treated with relaxin. Proc. Soc. Exp. Biol. Med. 190: 254–259.
5. FAILLI, P., S. NISTRI, S. QUATTRONE, et al. 2001. Relaxin up-regulates inducible nitric
oxide synthase expression and nitric oxide generation in rat coronary endothelial
cells. FASEB J. 16: 252–254.
6. BANI, D., P. FAILLI, M.G. BELLO, et al. 1998. Relaxin activates the L-arginine-nitric
oxide pathway in vascular smooth muscle cells in culture. Hypertension 31: 1240–
1247.
